Subscribe

PJSC Pharmsynthez (LIFE.ME)

RUB1.23 -0.08 (-5.77%)
RU MCX Healthcare Biotechnology
Address 25 Krasnovo Kursanta Str 197110
Saint Petersburg, RU
CEO Barkanova Anna Borisovna
Website pharmsynthez.com
IPO 2010-11-25
ISIN RU000A0JR514

Explore sections of this company profile

Description

PJSC Pharmsynthez, a pharmaceutical enterprise, focuses on the investigation, production, and supply of both proprietary (officinal) and generic active pharmaceutical ingredients across Russia and the Commonwealth of Independent States (CIS). Its portfolio of branded medicines includes Neovir, Segidrin, Fenasid, and Penkrofton, which are employed in critical therapeutic areas such as oncology, gynecology, the management of immune deficiencies, and tuberculosis. Public Joint-Stock Company Pharmsynthez has also established a collaboration with HiFiBiO Therapeutics Inks for the clinical advancement and market introduction of their SARS-CoV-2 neutralizing antibody within Russia. The company, which began operations in 1996, is headquartered in St. Petersburg, Russia.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
RUB1.23 -0.08 (-5.77%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7M
Beta
0.97
Float Shares
85.97M
Free Float %
28.6%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.38% -6.29% -9.23% -17.04% -13.46% -21.77% -23.61% -64.61% -52.55% -84.90% -89.14%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1.23
Quality scores
Altman Z-Score
-2.93
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Biotechnology: +1.6%
    -34.9% Q2'25: -73.0% (vs Q2'22)
  • ✓
    EPS growth Biotechnology: +29.7%
    +220.3% ★ Q2'25: +72.7% (vs Q2'22)
  • ✗
    FCF margin FCF growth · Biotechnology: +16.2%
    -21.9% Q2'25: -34.1% (vs Q2'22)
  • ✗
    EBIT margin Biotechnology: +0.0%
    -47.1% Q2'25: -67.9% (vs Q2'22)
  • ✗
    ROIC Biotechnology: -16.1%
    -4.6% ★ Q2'25: -7.7% (vs Q2'22)
  • ✗
    Share dilution Biotechnology: -3.4%
    +0.7% ★ Q2'25: +0.7% (vs Q2'22)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×
    -4.31× Q2'25: -2.34× (vs Q2'22)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.12) × ERP
WACC = 61% × Ke + 39% × Kd (6.2%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 1.23
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-30 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-29 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-28 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-27 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-26 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-25 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-24 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-23 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-22 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-21 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-20 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-19 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-18 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-17 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-16 C 2/5 1/5 1/5 1/5 2/5 1/5 4/5
2026-05-15 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-14 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-13 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-12 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-11 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-08 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-07 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-06 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-05 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-04 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-03 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-02 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-30 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-29 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-28 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-27 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-26 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-24 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-23 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-22 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-21 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-20 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-19 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-18 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-17 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5
2026-04-16 C 2/5 1/5 1/5 1/5 1/5 1/5 5/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-262.57M
OE per share TTM
-0.87
Owner's Yield
-33.20%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
93.2%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-978.4K
Shares Outstanding
301.01M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Barkanova Anna Borisovna Chief Accountant — —
Surkov Kirill Gennadievich Head of Research & Department and Member of Audit Commission — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Biotechnology